Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Castle Biosciences, Inc. - Common stock (NQ:CSTL)

24.76 -0.40 (-1.59%)
Streaming Delayed Price Updated: 2:20 PM EDT, Apr 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Castle Biosciences, Inc. - Common stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
News headline image
Castle Biosciences's Return On Capital Employed Overview ↗
According to data from Benzinga Pro, during Q2, Castle Biosciences's (NASDAQ:CSTL) reported sales totaled $34.84 million. Despite a 93.31% increase in earnings, the company posted a loss of $1.65... 
Via Benzinga
News headline image
Castle Biosciences to Participate in Upcoming Investor Conferences
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Host Investor Day on Sept. 20, 2022
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences: Q2 Earnings Insights ↗
  Castle Biosciences (NASDAQ:CSTL) reported its Q2 earnings results on Monday, August 8, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Castle Biosciences Reports Second Quarter 2022 Results
From Castle Biosciences, Inc.
Via Business Wire
News headline image
American Gastroenterological Association (AGA) Clinical Practice Update States That TissueCypher® May Be Beneficial for Risk-Stratification of Patients with Non-Dysplastic Barrett’s Esophagus
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Present at the Canaccord Genuity 42nd Annual Growth Conference
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Release Second Quarter 2022 Financial Results and Host Conference Call on Monday, August 8
From Castle Biosciences, Inc.
Via Business Wire
News headline image
DecisionDx®-Melanoma Ordered More Than 100,000 Times for Patients Diagnosed with Cutaneous Melanoma
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Presentation at 2022 AAD Innovation Academy to Showcase the Risk Stratification of DecisionDx®-Melanoma and its Role in the Management of Patients with Cutaneous Melanoma
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Honored with a 2022 Arizona Top Workplace Award
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Mosaic Tumbles Around 10%, Here's 71 Biggest Movers From Yesterday ↗
Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) shares jumped 263% to $2.73 on Thursday. Blue Hat Interactive terminated its previously proposed shelf takedown... 
Via Benzinga
News headline image
Patients with Uveal Melanoma Tested with DecisionDx®-UM Report Gaining Value from Test Results In Study Conducted In Collaboration with the Melanoma Research Foundation’s CURE OM Initiative
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Adds to Evidence Supporting Its Skin Cancer Test Portfolio through Multiple Data Presentations at the SDPA Annual Summer Dermatology Conference 2022
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Announces Support for OHSU’s War on Melanoma™
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Collaborative Study with Melanoma Research Foundation Confirms Patients Diagnosed with Melanoma Desire Testing with DecisionDx®-Melanoma
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Present at the JMP Securities Life Sciences Conference
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences’ DecisionDx®-Melanoma Test Receives 2022 MedTech Breakthrough Award
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Data Demonstrating DecisionDx®-Melanoma’s Ability to Risk-Stratify Patients According to Melanoma-Specific Survival to be Shared during the 2022 ASCO Annual Meeting
From Castle Biosciences, Inc.
Via Business Wire
News headline image
TissueCypher® Outperforms Pathologist Diagnoses When Predicting Progression in Patients Diagnosed with Barrett’s Esophagus with Low-Grade Dysplasia
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Grant From Research to Prevent Blindness and Castle Biosciences Supports Medical Student Research in Ocular Cancer
From Castle Biosciences
Via Business Wire
News headline image
Data from Second Independent Multi-Center Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Confirms Independent Risk-Stratification Performance of DecisionDx®-SCC
From Castle Biosciences, Inc.
Via Business Wire
News headline image
7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years ↗
Finding micro-cap stocks to buy requires a bit of everything, including patience. Today's plan is to pick from the top of the IWC ETF. 
Via InvestorPlace
News headline image
Castle Biosciences Collaborates with The Sun Bus to Provide Free Skin Cancer Screenings
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Reports First Quarter 2022 Results
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Camille Schrier, Miss America 2020, and Castle Biosciences Partner to Expand Awareness of Genetic Testing in Depression and Anxiety
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Recognizes Skin Cancer Awareness Month through Its Support of Patient-Focused Initiatives
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Announces Expanded U.S. Federal Supply Schedule Contract Covering Its Entire Dermatologic Cancer Portfolio of Tests
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Data from Independent, Pooled Analysis Show Significantly Improved Risk Predictions Over Clinical Variables for TissueCypher® Barrett’s Esophagus Test and Ability to Identify Patients at High Risk of Progressing to Esophageal Cancer
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Completes Acquisition of AltheaDx
From Castle Biosciences, Inc.
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.